News and Announcements

US FDA to review GSK bid to extend use of respiratory virus drug

By Frank Prenesti

Date: Monday 14 Jul 2025

(Sharecast News) - GSK said the US Food and Drug Administration has accepted an application for review to extend the indication of its Arexvy respiratory syncytial virus vaccine to adults aged 18-49 who are at increased risk.


The vaccine is approved in the US for the prevention of...

Sign up for free or to read the full story

Email this article to a friend

or share it with one of these popular networks:


Article Archive

Top of Page